Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

apceth Receives Approval for a Clinical Cancer Trial with Adult Mesenchymal Stem Cells

Published: Friday, June 14, 2013
Last Updated: Friday, June 14, 2013
Bookmark and Share
apceth's first innovative cellular anti-cancer drug based on modified mesenchymal stem cells enters Phase I / II of clinical testing.

apceth GmbH & Co. KG with its headquarters and manufacturing sites in Munich and Ottobrunn (near Munich) has received approval to conduct a clinical cancer trial with its genetically modified, adult mesenchymal stem cells.

This is an entirely new approach for the treatment of advanced types of cancer for which there is currently no effective treatment available.

The multicenter, open-label trial will recruit patients suffering from advanced adenocarcinomas of the gastrointestinal tract. This innovative therapy is based on mesenchymal stem cells harvested from the patient's own (autologous) bone marrow, which are processed, genetically modified and re-infused into the patient.

The stem cells thus modified specifically target the tumor and the cytotoxic gene product is selectively activated at the site of the tumor or its metastases to increase local efficacy and to reduce systemic toxicity, one of the main problems of systemic chemotherapy. This unique principle is also applicable to other cancer types.

This clinical trial will be initiated at the University Hospital Grosshadern in Munich in the next few weeks in collaboration with experts from the National Center of Tumor Diseases (NCT) in Heidelberg and the Karolinska Institute in Stockholm.

There is already broad international interest in expanding this trial and further developing this innovative therapy option.

John Marshall, Professor of Oncology and Director at the Lombardi Cancer Center of the Georgetown University in Washington, DC: "This is a very exciting new class of drugs based on adult stem cells delivering a true innovation for patients with advanced cancer. There is a clear unmet medical need for this and we are hopeful that we can begin testing in the US soon."

Also other leading cancer centers in the USA have already expressed their interest, such as the M.D. Anderson Cancer Center in Houston and the Fred Hutchinson Cancer Research Center in Seattle.

This to date unique and innovative approach in the treatment of cancer is part of apceth's corporate strategy of developing sustainable cell-based therapeutics.

Other clinical trials are already testing the treatment of advanced vascular diseases, while other cellular drugs are under development.

Besides its own internal research and development programs, apceth also collaborates with international pharmaceutical and biotech companies, who are showing increasing interest in cell- and gene therapeutics as a next-generation treatment option and entering the emerging field of "regenerative medicine".

While apceth is already being supported by numerous national and international grants, the company has just concluded another round of financing of € 22 m from their existing investors.

This will enable apceth to further develop its innovative cellular therapeutics right up to the clinical testing stage.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

apceth and University of Cologne to Join Forces
Combination aims to achieve high levels of activation of CART cells in tumors with reduced toxicity in normal tissues.
Saturday, July 11, 2015
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
Ovarian Cancer Insight
Study showed tumours release cytokines to attract macrophages, which secrete growth factors that in turn promote tumour growth.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Questioning the Safety of Selenium to Combat Cancer
Research indicates the need for change in practice as selenium supplements cannot be recommended for preventing colorectal cancer.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Transgenomic, Precipio Diagnostics Merger
Merger will creates a robust diagnostic platform focused on improving accuracy of cancer diagnoses.
Leukaemia Cell Movement Gives Clues to Tackling Treatment-Resistant Disease
Researchers at Imperial College London have suggested that the act of moving itself may help the cells to survive, possibly through short-lived interactions with an array of our own cells.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos